ArticlePloS one2025
Nationwide seroprevalence of SARS-CoV-2 during the COVID-19 pandemic and prepandemic periods in Lao PDR.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLao PDR reported a low number of confirmed SARS-CoV-2 cases until the introduction of COVID-19 vaccines in April 2021. This raised doubts about whether the reported number reflected the true situation and questioned about possible pre-existing immunity against SARS-CoV-2.
methodsWe retrospectively analyzed leftover blood donor samples collected in 2003-2004, 2015, and 2018 in Vientiane Capital, as well as samples collected in 2020 and between February and August 2021 across 18 provinces in Lao PDR to better understand the epidemiology of the infection. The samples were first screened using an anti-SARS-CoV-2 IgG ELISA (Euroimmun). The presence of anti-SARS-CoV-2 antibodies was then confirmed or refuted by testing positive and equivocal samples using anti-SARS-CoV-2 IgG CLIA (Beckman Coulter) targeting anti-Spike antibodies and SARS-CoV-2 virus neutralization test.
resultsAll pre-pandemic sera from Vientiane capital (79 in 2003-2004, 406 in 2015 and 191 in 2018), and all 2,225 sera collected in 2020 from eight provinces, tested negative. A total of 3,663 sera were collected prospectively in 2021 from 14 provinces. Bokeo and Oudomxay had the highest prevalence, each at 19.8%, followed by Luang Namtha at 16.1% and Salavan at 15.5%. However, the majority of samples collected from those four provinces were obtained after the outbreak surge and the introduction of COVID-19 vaccines in mid-April.
conclusionThere was no evidence of cross-reactive neutralizing antibodies prior to the COVID-19 pandemic and the seroprevalence of SARS-CoV-2 was confirmed to be low in Lao PDR before the introduction of COVID-19 vaccines and the surge in infections from May 2021.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.